Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Talk outline
- 2010 dengue burden
- Dengue virus global distribution
- When will dengue vaccines come online?
- Global dengue vaccine needs
- Severe vaccine shortage
- Vaccine delivery complexities
- Who must be immunized?
- DHF at Bangkok children’s hospital
- Infant DHF/DSS
- DSS in a 6 month-old infant with hepatomegaly
- How to vaccinate to protect babies
- Herd immunity, how is it measured?
- Dengue neutralizing antibodies, Thailand, 1980
- Dengue infections in Iquitos, Peru
- Fraction to vaccinate to achieve herd immunity
- Estimates of dengue
- Protection using a partially efficacious vaccine (1)
- Protection using a partially efficacious vaccine (2)
- Impact of no vaccination on infection rates
- Impact of vaccination on infection rates (2-14)
- Impact of vaccination on infection rates (2-46)
- How can dengue vaccines be improved?
- Simultaneous inoculation of 4 wt dengue viruses
- Tetravalent live-attenuated dengue viruses
- WRAIR/GSK tetravalent vaccine (30 days)
- WRAIR/GSK tetravalent vaccine (180 days)
- Under-immunization may result in ADE
- Intrinsic ADE
- Risk of dengue ADE
- Success of NIH tetravalent dengue vaccine
- How to improve existing dengue vaccines
- ChimeriVax dengue vaccine
- T cells may contribute to protection
- T cell responses differ between DENV 2 and 3
- Specific dengue immunity
- Quaternary structure of DENV Nt Abs
- 7 angstrom map of Fab 14C10 to DENV 1 virion
- Question to be answered
- Human dengue challenge model
- Assessing LAV strains for a human dengue model
- Preventing infection with near wild-type DENVs
- DENV 1 and DENV 3 summary
- Fully effective vaccine is still a work in progress
Topics Covered
- Projected availability of dengue vaccines
- Global dengue vaccine needs
- Vaccine delivery complexities
- How dengue vaccines can be improved
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Halstead, S. (2015, May 28). Dengue vaccine development: II. problems to be solved [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 7, 2024, from https://doi.org/10.69645/MBFV5714.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Scott Halstead has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Series: Vaccines
Transcript
Please wait while the transcript is being prepared...
0:00
So this is the second lecture on current dengue
vaccine development,
and in the first lecture
we described the vaccine
under current development,
and exactly where they are
in the development process.
Now we're going to talk about
how are we going to implement
these vaccines, how we're going
to use them, and what problems
can we expect, and how
can they be solved.
So problems to be solved.
0:27
And these are the topics that
we'll discuss in this lecture.
First, when will dengue
vaccines come online?
Second, what are the global
dengue vaccine needs?
Third, what are the
complexities that
we're going to have to confront
with, as we've seen, a Sanofi,
which is just a partially
efficacious vaccine,
it's not a 100% against
all four viruses.
How are we going to immunize the
two distinctly different groups
who are at risk to dengue disease?
And how can we stop or
reduce dengue transmission?
Fourth, how can dengue
vaccines be improved?
And here we need to understand
the complication of antibody
dependent enhancement,
abbreviated ADE,
and to understand better
how protection is induced
against dengue
infection and disease,
both in the natural setting,
and also from vaccines.
And here we're going to need
greater attention to and support
from basic research, and finally,
the use of a human challenge model
in which human beings
who have been vaccinated
will actually be challenged
by a live, somewhat modified
dengue virus.